• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    UK's Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions' Fingerprint Drug Test to Enhance Workplace Safety

    9/25/24 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email

    NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.

    "We are thrilled to partner with Intelligent Fingerprinting to enhance our approach to workplace safety," said Emma Bullock, Head of People at Thanet Earth. "Fingerprint drug testing allows us to ensure that our team is operating in a safe and efficient manner without interrupting our daily operations."

    Thanet Earth is a leader in the UK's horticultural sector, producing millions of tomatoes, cucumbers, and peppers annually for major retailers nationwide. The company is renowned for its state-of-the-art approach to sustainable farming, integrating cutting-edge technology to optimize yield and environmental impact.

    With the implementation of the Intelligent Fingerprinting Drug Screening System, Thanet Earth will be able to conduct workplace drug testing quickly, discreetly, and effectively. This capability is crucial in maintaining safety within the high-paced food production environment, where even minor disruptions can have significant downstream effects.

    About Intelligent Bio Solutions Inc.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. 

    For more information, visit: http://www.ibs.inc/

    About Thanet Earth

    Thanet Earth is the UK's largest greenhouse complex. Situated in Kent, it produces a significant portion of the nation's salad crops, with a focus on sustainability and innovation. The facility uses cutting-edge technology to maximize efficiency and minimize environmental impact, ensuring the production of high-quality salad crops (or) fresh produce year-round.

    For more information, visit: https://www.thanetearth.com/

    Forward-Looking Statements:  

    Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  

    Company Contact:  

    Intelligent Bio Solutions Inc.  

    [email protected]  

    Investor & Media Contact:   

    Valter Pinto, Managing Director   

    KCSA Strategic Communications   

    PH: (212) 896-1254   

    [email protected]



    Primary Logo

    Get the next $INBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

    Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a

    2/25/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout

    NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS's fingerprint drug screening technology across its UK operations. The partnership reflects a shift from third-party testing services to an in-house solution, driven by superior hygiene protocols, operational efficiency, and demonstrated cost savings, validated through joint Return on Investment ("ROI") a

    2/24/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/31/25 4:15:27 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:16 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:15 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/25/26 9:15:25 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/12/26 8:55:44 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Intelligent Bio Solutions Inc.

    10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/12/26 8:31:15 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care